38928248|t|Emerging Therapeutic Potential of Fluoxetine on Cognitive Decline in Alzheimer's Disease: Systematic Review.
38928248|a|Fluoxetine, a commonly prescribed medication for depression, has been studied in Alzheimer's disease (AD) patients for its effectiveness on cognitive symptoms. The aim of this systematic review is to investigate the therapeutic potential of fluoxetine in cognitive decline in AD, focusing on its anti-degenerative mechanisms of action and clinical implications. According to PRISMA, we searched MEDLINE, up to 1 April 2024, for animal and human studies examining the efficacy of fluoxetine with regard to the recovery of cognitive function in AD. Methodological quality was evaluated using the ARRIVE tool for animal AD studies and the Cochrane tool for clinical trials. In total, 22 studies were analyzed (19 animal AD studies and 3 clinical studies). Fluoxetine promoted neurogenesis and enhanced synaptic plasticity in preclinical models of AD, through a decrease in Abeta pathology and increase in BDNF, by activating diverse pathways (such as the DAF-16-mediated, TGF-beta1, ILK-AKT-GSK3beta, and CREB/p-CREB/BDNF). In addition, fluoxetine has anti-inflammatory properties/antioxidant effects via targeting antioxidant Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome. Only three clinical studies showed that fluoxetine ameliorated the cognitive performance of people with AD; however, several methodological issues limited the generalizability of these results. Overall, the high-quality preclinical evidence suggests that fluoxetine may have neuroprotective, antioxidant, and anti-inflammatory effects in AD animal models. While more high-quality clinical research is needed to fully understand the mechanisms underlying these effects, fluoxetine is a promising potential treatment for AD patients. If future clinical trials confirm its anti-degenerative and neuroprotective effects, fluoxetine could offer a new therapeutic approach for slowing down the progression of AD.
38928248	34	44	Fluoxetine	Chemical	MESH:D005473
38928248	48	65	Cognitive Decline	Disease	MESH:D003072
38928248	69	88	Alzheimer's Disease	Disease	MESH:D000544
38928248	109	119	Fluoxetine	Chemical	MESH:D005473
38928248	158	168	depression	Disease	MESH:D003866
38928248	190	209	Alzheimer's disease	Disease	MESH:D000544
38928248	211	213	AD	Disease	MESH:D000544
38928248	215	223	patients	Species	9606
38928248	249	267	cognitive symptoms	Disease	MESH:D019954
38928248	350	360	fluoxetine	Chemical	MESH:D005473
38928248	364	381	cognitive decline	Disease	MESH:D003072
38928248	385	387	AD	Disease	MESH:D000544
38928248	548	553	human	Species	9606
38928248	588	598	fluoxetine	Chemical	MESH:D005473
38928248	652	654	AD	Disease	MESH:D000544
38928248	726	728	AD	Disease	MESH:D000544
38928248	826	828	AD	Disease	MESH:D000544
38928248	862	872	Fluoxetine	Chemical	MESH:D005473
38928248	953	955	AD	Disease	MESH:D000544
38928248	979	984	Abeta	Gene	351
38928248	1011	1015	BDNF	Gene	627
38928248	1078	1087	TGF-beta1	Gene	7040
38928248	1089	1092	ILK	Gene	3611
38928248	1093	1096	AKT	Gene	207
38928248	1097	1105	GSK3beta	Gene	2932
38928248	1111	1115	CREB	Gene	1385
38928248	1118	1122	CREB	Gene	1385
38928248	1123	1127	BDNF	Gene	627
38928248	1143	1153	fluoxetine	Chemical	MESH:D005473
38928248	1163	1175	inflammatory	Disease	MESH:D007249
38928248	1233	1237	Nrf2	Gene	4780
38928248	1238	1242	HO-1	Gene	3162
38928248	1257	1261	TLR4	Gene	7099
38928248	1262	1267	NLRP3	Gene	114548
38928248	1322	1332	fluoxetine	Chemical	MESH:D005473
38928248	1386	1388	AD	Disease	MESH:D000544
38928248	1537	1547	fluoxetine	Chemical	MESH:D005473
38928248	1596	1608	inflammatory	Disease	MESH:D007249
38928248	1620	1622	AD	Disease	MESH:D000544
38928248	1751	1761	fluoxetine	Chemical	MESH:D005473
38928248	1801	1803	AD	Disease	MESH:D000544
38928248	1804	1812	patients	Species	9606
38928248	1899	1909	fluoxetine	Chemical	MESH:D005473
38928248	1985	1987	AD	Disease	MESH:D000544
38928248	Association	MESH:D000544	1385
38928248	Positive_Correlation	MESH:D005473	3611
38928248	Association	MESH:D000544	351
38928248	Negative_Correlation	MESH:D005473	MESH:D003072
38928248	Positive_Correlation	MESH:D005473	207
38928248	Negative_Correlation	MESH:D005473	MESH:D000544
38928248	Association	MESH:D005473	4780
38928248	Association	MESH:D005473	7099
38928248	Negative_Correlation	MESH:D005473	114548
38928248	Negative_Correlation	MESH:D005473	MESH:D003866
38928248	Positive_Correlation	MESH:D005473	627
38928248	Association	MESH:D000544	2932
38928248	Negative_Correlation	MESH:D005473	351
38928248	Negative_Correlation	MESH:D005473	MESH:D019954
38928248	Positive_Correlation	MESH:D005473	2932
38928248	Negative_Correlation	MESH:D005473	MESH:D007249
38928248	Association	MESH:D000544	7040
38928248	Association	MESH:D005473	3162
38928248	Positive_Correlation	MESH:D005473	1385
38928248	Positive_Correlation	MESH:D005473	7040

